ArticleCureus2026
Maternal Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Vaccination in Panama: A Retrospective Follow-Up Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPanama introduced routine maternal bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccination (Abrysvo, Pfizer Inc., New York, NY) in July 2025. We described common retrospectively self-reported reactions and maternal, perinatal, and neonatal conditions among the first 200 eligible recipients enrolled in active follow-up.
methodsThis retrospective descriptive cohort included women aged 18 years or older who received RSVpreF at 32.0-36.6 weeks of gestation from July through December 2025 and completed one structured interview, generally after delivery, from January through July 2026. Exact vaccination-to-interview intervals were unavailable. Frequencies and Wilson 95% confidence intervals were calculated.
resultsOf 225 completed questionnaires, 200 met the eligibility criteria. The mean maternal age was 28.1 years (standard deviation = 6.4). Any reaction was reported by 55.5% (95% CI: 48.6%-62.2%), most often injection-site pain (48.0%), and self-reported fever occurred in 2.5%. A participant-reported hypertensive disorder occurred in 12.0%. Four births were preterm (2.0%), and five newborns had low birth weight (2.5%). Participant-reported jaundice was the most frequent neonatal condition (20.0%).
conclusionsReported reactions were mainly local and short-lived. These findings describe early implementation in Panama but do not assess vaccine effectiveness, comparative safety, rare-event risk, or causality. Convenience recruitment, post-delivery selection, retrospective recall, absence of clinical verification and a comparator, and missing baseline risk and event-timing data limit interpretation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.